EUVIMEDEUVIMED entdecken
Open Access

A synergistic interaction between PRMT5 and LSD1 inhibitors in AML

Nesteene Joy Param iD, Elisa Arceci iD, Francesco Fiorentino iD, Luca Pignata iD, Denis Torre iD, Nayeli Gutiérrez-Trejo iD, Jia Yi Fong, Pierre-Alexis Goy iD, Brenda Y Han iD, Chiara Lambona, Elisabetta Di Bello, Carola Castiello und 17 weitere

Science Advances · 2026

DOI: 10.1126/sciadv.aea4059 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Nesteene Joy Param und 28 weiteren Autor:innen. Beteiligte Einrichtung: Center for OncoGenomics and Innovative Therapeutics (COGIT); Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacologica…. Hauptthemen laut MEDLINE: Protein-Arginine N-Methyltransferases, Histone Demethylases, Leukemia, Myeloid, Acute, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Institutes of Health, Georgia Clinical and Translational Science Alliance, Marie Sklodowska-Curie Actions.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a hematopoietic malignancy caused by abnormal proliferation and differentiation of blasts. PRMT5, a methyltransferase that catalyzes symmetric dimethylation of arginine (SDMA) residues, has been implicated in cancer stem cell homeostasis and shown to be a potential therapeutic target in AML. However, given the toxicity of complete PRMT5 inhibition, there is a need to identify effective synergistic therapies. Through a targeted screen of compounds that inhibit key nodes of PRMT5-regulated pathways, we identified a synthetic lethality between inhibition of PRMT5 and LSD1, a lysine demethylase known to affect AML blast differentiation. The two inhibitors broadly reshape the transcriptome of targeted cells and synergize to promote AML differentiation and eventually growth inhibition and apoptosis, in a p53-dependent manner. To leverage this synthetic lethal interaction, we generated new dual compounds to inhibit both enzymes and recapitulated the effects of the drug combination. Our results uncover an unexpected convergence of PRMT5- and LSD1-regulated targets, paving the way for new therapeutic opportunities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein-Arginine N-MethyltransferasesHistone DemethylasesLeukemia, Myeloid, AcuteEnzyme InhibitorsHumansDrug SynergismApoptosisCell Line, TumorCell DifferentiationCell ProliferationTumor Suppressor Protein p53

Substanzen

Protein-Arginine N-MethyltransferasesHistone DemethylasesKDM1A protein, humanPRMT5 protein, humanEnzyme InhibitorsTumor Suppressor Protein p53

Autor:innen und Institutionen

  • Center for OncoGenomics and Innovative Therapeutics (COGIT); Center for Therapeutics Discovery, Department of Oncological Sciences and Pharmacological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount…
  • Department of Drug Chemistry and Technologies, Sapienza University of Rome, 00185 Rome, Italy.
  • Department of Biochemical Sciences, Sapienza University of Rome, 00185 Rome, Italy.
  • Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore 138673, Singapore.
  • Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119077, Singapore.
  • Department of Biology and Biotechnology, University of Pavia, 27100 Pavia, Italy.

ORCID-Profile: Nesteene Joy Param, Elisa Arceci, Francesco Fiorentino, Luca Pignata, Denis Torre, Nayeli Gutiérrez-Trejo, Pierre-Alexis Goy, Brenda Y Han, Marco Barone, Cheryl Arrowsmith, Koichi Ito, Peggy Scherle, Steven Ndoye, Tommaso Tabaglio, Anand D Jeyasekharan, Manikandan Lakshmanan, Hansjörg Habisch, Tobias Madl, Andrea Mattevi, Sergio Valente, Antonello Mai, Ernesto Guccione

Förderung

  • National Institutes of Health
  • Georgia Clinical and Translational Science Alliance
  • Marie Sklodowska-Curie Actions
  • Cancer Center, University of Florida Health
  • National Cancer Institute, Cairo University
  • Ricerca sul Cancro
  • Ateneo Sapienza Project

Zitieren

APA

Param, N. J., Arceci, E., Fiorentino, F., Pignata, L., Torre, D., Gutiérrez-Trejo, N., Fong, J. Y., Goy, P. A., Han, B. Y., Lambona, C., Di Bello, E., Castiello, C., Barone, M., Schwarz, M., Arrowsmith, C., Ito, K., Scherle, P., Wee, D. K. B., Ndoye, S., …, & Guccione, E. (2026). A synergistic interaction between PRMT5 and LSD1 inhibitors in AML. Science Advances. https://doi.org/10.1126/sciadv.aea4059

Vancouver

Param NJ, Arceci E, Fiorentino F, Pignata L, Torre D, Gutiérrez-Trejo N, et al. A synergistic interaction between PRMT5 and LSD1 inhibitors in AML. Science Advances. 2026. doi:10.1126/sciadv.aea4059

BibTeX
@article{Param2026,
  author = {Param, Nesteene Joy and Arceci, Elisa and Fiorentino, Francesco and Pignata, Luca and Torre, Denis and Gutiérrez-Trejo, Nayeli and Fong, Jia Yi and Goy, Pierre-Alexis and Han, Brenda Y and Lambona, Chiara and Di Bello, Elisabetta and Castiello, Carola and Barone, Marco and Schwarz, Megan and Arrowsmith, Cheryl and Ito, Koichi and Scherle, Peggy and Wee, Dave Keng Boon and Ndoye, Steven and Tabaglio, Tommaso and Jeyasekharan, Anand D and Lakshmanan, Manikandan and Cirilli, Roberto and Habisch, Hansjörg and Madl, Tobias and Mattevi, Andrea and Valente, Sergio and Mai, Antonello and Guccione, Ernesto},
  title = {A synergistic interaction between PRMT5 and LSD1 inhibitors in AML},
  journal = {Science Advances},
  year = {2026},
  doi = {10.1126/sciadv.aea4059}
}
Kostenlos starten →